Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$0.55
+1.9%
$0.69
$0.50
$1.95
$5.91M1.6220,557 shs426 shs
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
$0.07
-6.6%
$0.08
$0.06
$1.31
$727K1.3922,874 shs6,000 shs
Imunon, Inc. stock logo
CLSN
Imunon
$2.22
$1.80
$15.75
$13.91M2.27150,471 shs711 shs
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$8.15
+2.1%
$8.39
$5.01
$10.75
$10.46M0.88173,014 shs1,817 shs
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$3.53
$1.12
$11.30
$96.26M2.274.33 million shs1.20 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
0.00%-16.34%-14.29%-10.00%-56.45%
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
0.00%0.00%0.00%-25.20%-77.68%
Imunon, Inc. stock logo
CLSN
Imunon
0.00%0.00%0.00%0.00%0.00%
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
-2.11%-1.62%-12.32%+53.10%+32.60%
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
2.00
HoldN/AN/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
2.00
HoldN/AN/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest ADXS, BLCM, GHSI, CLSN, and SNSS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/2/2024
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
$10K591.25N/AN/A($2.27) per share-0.24
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
$1.50M0.48N/AN/A$0.23 per share0.33
Imunon, Inc. stock logo
CLSN
Imunon
$500K0.00N/AN/A$9.66 per share0.00
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$12.25M0.85$0.14 per share59.51$6.39 per share1.28
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
$2.07M0.00N/AN/A$1.42 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
-$48.07M-$7.98N/AN/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
-$24.97MN/A0.00N/AN/AN/A-157.93%N/A
Imunon, Inc. stock logo
CLSN
Imunon
-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
$160K$0.1174.10N/A0.51%2.01%1.21%5/20/2024 (Estimated)
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
-$23.33M-$2.70N/AN/AN/AN/A-179.05%-72.27%N/A

Latest ADXS, BLCM, GHSI, CLSN, and SNSS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A$0.33+$0.33$0.33N/A$21.56 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/AN/AN/AN/AN/A
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/AN/AN/AN/AN/A
Imunon, Inc. stock logo
CLSN
Imunon
N/AN/AN/AN/AN/A
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/AN/AN/AN/AN/A
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A
0.30
0.30
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
N/A
3.04
3.04
Imunon, Inc. stock logo
CLSN
Imunon
0.13
6.52
6.52
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
N/A
9.01
6.98
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
N/A
7.74
7.74

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Ayala Pharmaceuticals, Inc. stock logo
ADXS
Ayala Pharmaceuticals
N/A10.75 million10.68 millionNot Optionable
Bellicum Pharmaceuticals, Inc. stock logo
BLCM
Bellicum Pharmaceuticals
139.72 million8.72 millionNot Optionable
Imunon, Inc. stock logo
CLSN
Imunon
277.10 million6.77 millionOptionable
Guardion Health Sciences, Inc. stock logo
GHSI
Guardion Health Sciences
91.28 million1.27 millionNot Optionable
Sunesis Pharmaceuticals, Inc. stock logo
SNSS
Sunesis Pharmaceuticals
2418.09 millionN/AOptionable

ADXS, BLCM, GHSI, CLSN, and SNSS Headlines

SourceHeadline
AQSZF Aequus Pharmaceuticals Inc.AQSZF Aequus Pharmaceuticals Inc.
seekingalpha.com - December 20 at 5:25 AM
4 Breakout Stocks to Watch Going Into Labor Day4 Breakout Stocks to Watch Going Into Labor Day
thestreet.com - August 6 at 7:27 PM
4 Stocks Under $10 to Trade Now4 Stocks Under $10 to Trade Now
thestreet.com - January 14 at 10:56 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Ayala Pharmaceuticals logo

Ayala Pharmaceuticals

NASDAQ:ADXS
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Bellicum Pharmaceuticals logo

Bellicum Pharmaceuticals

NASDAQ:BLCM
Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.
Imunon logo

Imunon

NASDAQ:CLSN
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Guardion Health Sciences logo

Guardion Health Sciences

NASDAQ:GHSI
Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported nutrition, medical foods, and dietary supplements in North America and Europe, and Internationally. The company offers Lumega-Z, a medical food that replenishes and restores the macular protective pigment; and GlaucoCetin, a vision-specific medical food to support and protect the mitochondrial function of optic nerve cells, as well as improve blood flow in the ophthalmic artery in patients with glaucoma. It develops ImmuneSF, a nutraceutical formulation, as well as a portfolio of nutraceutical products under the NutriGuard brand. Further, it distributes medical foods products through e-commerce in an online store, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.
Sunesis Pharmaceuticals logo

Sunesis Pharmaceuticals

NASDAQ:SNSS
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.